The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen-Reference-Cited by-同舟云学术

The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen

Published:2017-10-27 Issue:21 Volume:60 Page:8989-9002
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Riggs Jennifer R.¹^ORCID,Nagy Mark¹,Elsner Jan¹,Erdman Paul¹,Cashion Dan¹,Robinson Dale¹,Harris Roy¹,Huang Dehua¹,Tehrani Lida¹,Deyanat-Yazdi Gordafaried¹,Narla Rama Krishna¹,Peng Xiaohui¹,Tran Tam¹,Barnes Leo¹,Miller Terra¹,Katz Jason¹,Tang Yang¹,Chen Ming¹,Moghaddam Mehran F.¹,Bahmanyar Sogole¹,Pagarigan Barbra¹,Delker Silvia¹,LeBrun Laurie¹,Chamberlain Philip P.¹^ORCID,Calabrese Andrew¹,Canan Stacie S.¹,Leftheris Katerina¹,Zhu Dan¹,Boylan John F.¹

Affiliation:

1. Celgene Corporation, 10300 Campus Pointe Drive, Suite 100, San Diego, California 92121, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.7b01223

Reference36 articles.

1. How were new medicines discovered?

2. The discovery of first-in-class drugs: origins and evolution

3. Phenotypic screening in cancer drug discovery — past, present and future

4. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

5. Calabrese, A. C.; Jeffy, B.; Robinson, D.; Zhu, D.; Huang, D.; Elsner, J.; Boylan, J.; Tehrani, L.; Nagy, M. A.; Raheja, R. K.; Erdman, P.; Narla, R. K.; Harris, R. L.; Tran, T. M.; Riggs, J.; Ning, Y.; Xu, S.Substituted Pyrrolopyrimidine Compounds, Compositions Thereof, and Methods of Treatment Therewith. U.S. Patent 9,346,812, May 24, 2016.

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hijacking monopolar spindle 1 (MPS1) for various cancer types by small molecular inhibitors: Deep insights from a decade of research and patents;European Journal of Medicinal Chemistry;2024-07

2. In silico identification of a novel Cdc2‐like kinase 2 (CLK2) inhibitor in triple negative breast cancer;Protein Science;2024-05-09

3. Discovery of a potent and selective covalent threonine tyrosine kinase (TTK) inhibitor;Bioorganic Chemistry;2024-02

4. Access to Cyclopropanol via Supply-Centered Synthesis;Organic Process Research & Development;2024-01-09

5. Development of MPS1 Inhibitors: Recent Advances and Perspectives;Journal of Medicinal Chemistry;2023-12-14